Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.
Meta HM Diekstra,
Jesse J Swen,
Loes FM van der Zanden,
Sita H Vermeulen,
Epie Boven,
Ron HJ Mathijssen,
Koya Fukunaga,
Taisei Mushiroda,
Fumiya Hongo,
Egbert Oosterwijk,
Anne Cambon-Thomsen,
Daniel Castellano,
Achim Fritsch,
Jesus Garcia Donas,
Cristina Rodriguez-Antona,
Rob Ruijtenbeek,
Marius T Radu,
Tim Eisen,
Kerstin Junker,
Max Roessler,
Ulrich Jaehde,
Tsuneharu Miki,
Stefan Böhringer,
Michiaki Kubo,
Lambertus ALM Kiemeney,
Henk-Jan Guchelaar
Jul 24, 2022
Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide...